Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: A class action lawsuit has been filed against aTyr Pharma, Inc. following allegations of securities law violations by the company and certain executives. The lawsuit claims that the defendants made misleading statements about the drug Efzofitimod, falsely portraying its efficacy and downplaying risks associated with stopping steroid use. Investors who suffered losses during the defined 'Class Period' are urged to join the lawsuit. The firm representing the investors typically operates on a contingency fee basis, meaning they only collect fees if the case is won.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against aTyr Pharma for alleged securities law violations.
  • Defendants accused of making false and misleading statements regarding Efzofitimod.
  • Investors may have purchased shares at artificially inflated prices due to these misrepresentations.
  • Shareholders faced substantial losses linked to these legal allegations.

Full Press Release Details

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securities between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ATYR.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors regarding the efficacy of Efzofitimod; (2) At the same time, Defendants disseminated false and misleading statements and/or concealed material adverse facts concerning the drug’s actual capability—particularly its ability to enable patients to completely taper their steroid usage; and (3) As a result of these omissions and misrepresentations, Plaintiff and other shareholders purchased aTyr’s securities at artificially inflated prices.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ATYR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in aTyr you have until December 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the class action lawsuit about aTyr Pharma?

The lawsuit claims aTyr Pharma and its officers violated federal securities laws.

Who can join the aTyr Pharma class action?

Investors who purchased aTyr securities between January 16 and September 12, 2025, can join.

What were the allegations against aTyr's Defendants?

They allegedly made false statements about the drug Efzofitimod’s efficacy.

What is the deadline to request lead plaintiff status?

You must request lead plaintiff status by December 8, 2025.

Is there a cost for participating in the lawsuit?

No, there is no cost. The firm works on a contingency fee basis.

Last updated: Dec 5, 2025